EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Combination Treatment Strategies to Overcome PARP Inhibitor Resistance

Young-Hwa Soung, Jun Chung

Biomolecules · 03.10.2023 · 13 (10) · 1480

DOI: 10.3390/biom13101480 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 03.10.2023. Verfasst von Young-Hwa Soung und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH grant R01, Peter T. Rowley Breast Cancer Research Projects (Round 7).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Poly(ADP-ribose) polymerase (PARP) enzymes have been shown to be essential for DNA repair pathways, including homologous recombination repair (HRR). Cancers with HRR defects (e.g., BRCA1 and BRCA2 mutations) are targets for PARP inhibitors (PARPis) based on the exploitation of “synthetic lethality”. As a result, PARPis offer a promising treatment option for advanced ovarian and breast cancers with deficiencies in HRR. However, acquired resistance to PARPis has been reported for most tumors, and not all patients with BRCA1/2 mutations respond to PARPis. Therefore, the formulation of effective treatment strategies to overcome resistance to PARPis is urgently necessary. This review summarizes the molecular mechanism of therapeutic action and resistance to PARPis, in addition to emerging combination treatment options involving PARPis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsAntineoplastic AgentsFemaleHumansPoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinBRCA2 ProteinPoly(ADP-ribose) Polymerases

Stichwörter der Autor:innen

PARP inhibitorsPARP-1breast cancerscombination therapyhomologous recombination deficiencyovarian cancersresistance

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBRCA1 protein, humanBRCA1 ProteinBRCA2 protein, humanBRCA2 ProteinAntineoplastic AgentsPoly(ADP-ribose) Polymerases

Autor:innen und Institutionen

  • Department of Pathology, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.

Förderung

  • NCI NIH HHS
  • NIH grant R01
  • Peter T. Rowley Breast Cancer Research Projects (Round 7)

Zitieren

APA

Soung, Y. H., & Chung, J. (2023). Combination Treatment Strategies to Overcome PARP Inhibitor Resistance. Biomolecules, 13(10), 1480. https://doi.org/10.3390/biom13101480

Vancouver

Soung YH, Chung J. Combination Treatment Strategies to Overcome PARP Inhibitor Resistance. Biomolecules. 2023;13(10):1480. doi:10.3390/biom13101480

BibTeX
@article{Soung2023,
  author = {Soung, Young-Hwa and Chung, Jun},
  title = {Combination Treatment Strategies to Overcome PARP Inhibitor Resistance},
  journal = {Biomolecules},
  year = {2023},
  volume = {13},
  number = {10},
  pages = {1480},
  doi = {10.3390/biom13101480}
}
Kostenlos starten →